Skip to main content

ICICI Bank likely to see significant jump in Q2 profit, but loan growth may slow down

Net interest income is expected to be more than 12 percent year-on-year with slowing down loan growth to around 5-6 percent YoY, but deposits growth could be around 18-20 percent YoY.

The country's second largest private sector lender, ICICI Bank, on October 31, is expected to report significant year-on-year growth in September quarter profit due to low base in the year-ago period. In Q2FY20, profit was affected by deferred tax assets hit following change in corporate tax rate by the government.

Profit is likely to be in the wide range of Rs 3,000-4,000 crore against Rs 655 crore in same period last year. Provisions may remain elevated on year-on-year basis, but the sequentially may decline as the bank already made high contingent provisions for likely COVID-19 related defaults.

Net interest income is expected to be more than 12 percent year-on-year with slowing down loan growth to around 5-6 percent YoY, but deposits growth could be around 18-20 percent YoY.

"We expect a pre-provision operating profit (PPoP) growth of around 15 percent YoY with NII growth at 12 percent YoY partly aided by operating leverage. Loan growth to slow to around 6 percent but NIM (core) to remain stable QoQ at 3.7 percent," said Kotak Institutional Equities which sees 547.6 percent YoY growth in Q2 profit.

"We expect provisions to remain high but lower than the previous quarter as we don't see the bank making the same quantum of contingent provisions as we saw in Q1FY21. We expect focus to remain on the expected restructuring by Q4FY21," the brokerage added.



HDFC Securities also expects loan growth to slow further to 5.7 percent YoY, and core earnings to grow at 13 percent YoY.

Incremental COVID-19 related provisions, comments on collection efficiency, and movement in BB and below-rated book and outlook on asset quality (including restructuring) would be key factors to watch out for, said the brokerage.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...